{"title":"刺猬蛋白抑制剂sonidegib治疗1例单侧基底细胞癌。","authors":"Maria Alessandra Mattioli, Valentina Benzecry, Giulia Murgia, Nerina Denaro, Angelo Valerio Marzano, Emanuela Passoni, Gianluca Nazzaro","doi":"10.4081/dr.2024.10152","DOIUrl":null,"url":null,"abstract":"<p><p>Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer. BCCs are categorized into \"easy-to-treat\" and \"difficult-to-treat\" groups, with the latter including all BCCs that are challenging to manage due to technical, patient-related, or tumor-related factors, such as locally advanced BCCs. In this report, we describe an 84-year-old patient with an extensive, unilateral BCC. Following a decision by the multidisciplinary skin cancer board, the patient was successfully treated with a daily dose of 200 mg of sonidegib, an inhibitor of the Hedgehog pathway, for eight months, acquiring complete clinical and histopathological remission. No significant side effects were reported. The follow-up period of 24 months has shown no negative results.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210352/pdf/","citationCount":"0","resultStr":"{\"title\":\"A large unilateral basal cell carcinoma treated with Hedgehog inhibitor sonidegib: a case report.\",\"authors\":\"Maria Alessandra Mattioli, Valentina Benzecry, Giulia Murgia, Nerina Denaro, Angelo Valerio Marzano, Emanuela Passoni, Gianluca Nazzaro\",\"doi\":\"10.4081/dr.2024.10152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer. BCCs are categorized into \\\"easy-to-treat\\\" and \\\"difficult-to-treat\\\" groups, with the latter including all BCCs that are challenging to manage due to technical, patient-related, or tumor-related factors, such as locally advanced BCCs. In this report, we describe an 84-year-old patient with an extensive, unilateral BCC. Following a decision by the multidisciplinary skin cancer board, the patient was successfully treated with a daily dose of 200 mg of sonidegib, an inhibitor of the Hedgehog pathway, for eight months, acquiring complete clinical and histopathological remission. No significant side effects were reported. The follow-up period of 24 months has shown no negative results.</p>\",\"PeriodicalId\":11049,\"journal\":{\"name\":\"Dermatology Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210352/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/dr.2024.10152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2024.10152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
A large unilateral basal cell carcinoma treated with Hedgehog inhibitor sonidegib: a case report.
Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer. BCCs are categorized into "easy-to-treat" and "difficult-to-treat" groups, with the latter including all BCCs that are challenging to manage due to technical, patient-related, or tumor-related factors, such as locally advanced BCCs. In this report, we describe an 84-year-old patient with an extensive, unilateral BCC. Following a decision by the multidisciplinary skin cancer board, the patient was successfully treated with a daily dose of 200 mg of sonidegib, an inhibitor of the Hedgehog pathway, for eight months, acquiring complete clinical and histopathological remission. No significant side effects were reported. The follow-up period of 24 months has shown no negative results.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
